Release
2019/04/15

SHIONOGI ANNOUNCES DATA DEMONSTRATING POTENT IN VITRO ACTIVITY OF CEFIDEROCOL AGAINST THE MOST CRITICAL PRIORITY GRAM-NEGATIVE BACTERIAL PATHOGENS